^
    Back
    Association details:
    Biomarker:PIK3CA mutation
    Cancer:HER2 Positive Breast Cancer
    Drug:MEN1611 (PI3K inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

    Excerpt:
    ...- Advanced or metastatic breast cancer harbouring PIK3CA mutation on tissue sample...
    Trial ID:
    B-PRECISE-01
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Breast Cancer Res Treat
    Title:

    Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer

    Published date:
    03/13/2023
    Excerpt:
    Here we investigate the activity of the PI3K inhibitor MEN1611 at both molecular and phenotypic levels by dissecting and comparing its profile and efficacy in HER2 + breast cancer models with other PI3K inhibitors....In vivo, MEN1611 monotherapy showed significant and durable antitumor activity in several trastuzumab-resistant PIK3CA-mutant HER2 + PDX models. The combination of trastuzumab and MEN1611 significantly improved the efficacy compared to single agent treatment.
    DOI:
    10.1007/s00432-023-04670-w
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    SABCS 2020
    Title:

    Men1611 is a pi3k a/ß selective and d sparing inhibitor with long-lasting antitumor activity in different genetic backgrounds of pik3ca mutant breast cancer models

    Published date:
    11/17/2020
    Excerpt:
    MEN1611 monotherapy showed significant and long-lasting antitumor activity, reflected in tumor-stasis or tumor regression in several trastuzumab-resistant PIK3CA-mutant HER2 positive PDXs with different concomitant genomic aberrations.